Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.21.2
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2021
Disclosure Text Block [Abstract]  
STOCKHOLDERS' EQUITY
NOTE F - STOCKHOLDERS’ EQUITY
 
Common Stock
 
In the first nine months of 2021, the Company issued 62,332 shares of its common stock upon the exercise of stock options. These option exercises consisted of 50,000 and 12,332 shares issued to a director and employees, respectively.

On
March
26,
2021,
the
Company
issued
1,586,786
shares
of
its
common
stock
to
the
holder
of
a
convertible
promissory
note
upon
the conversion, on the original terms of the note, of the entire outstanding balance, principal and accrued interest, for that note, which
was
$476,036.
On April 15, 2021, the Company issued 830,526 shares of its common stock as consideration for the acquisition of ATI. The shares were valued at $5 million, based on an agreed formula based on the shares trading price.
 
On April 16, 2021 the Company issued 496,000 shares of its common stock and warrants to purchase an additional 19,840 shares of common stock, all for $3.1 million in a private sale to three accredited investors.
 
On June 1, 2021, the Company issued 53,723 shares of its common stock to various note holders upon the conversion of, or as payment for the entire outstanding balance, principal and accrued interest, of notes, all in accordance with the original terms of the notes, having an outstanding balance of $308,889 in the aggregate.
 
On June 30, 2021, 1,181,819 shares of its common stock became issuable upon the delivery to the Company of notices of conversion for the conversion of all the outstanding shares of the Company’s Series B Convertible Preferred Stock. The new shares of common stock and the new certificates will be issued to the former holders of the preferred stock upon the tender of lost certificate documentation by the holders.
 
Series B Convertible Preferred Stock
 
On November 6, 2007, the Company sold a total of 13,000 shares of Series B Convertible Preferred Stock (“Series B Shares”) to two investors for an aggregate purchase price of $1.3 million, less offering costs of $9,265. Each share of the Series B Shares has a stated value of $100.
 
The Series B Shares were convertible into shares of the Company’s Common Stock.  As of June 30, 2021, the two holders of the shares of preferred stock tendered notices of conversion, and all of the outstanding shares of Series B Convertible Preferred Stock were converted into 1,181,819 shares of the Company’s common stock.  As a result, effective as of June 30, 2021, the Company had no outstanding Series B Convertible Preferred Stock.